ArticleScientific reports2026
Tibial transverse transport promotes diabetic foot ulcer healing by regulating miR-182-5p.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcers (DFUs) represent a major complication of diabetes, characterized by impaired wound healing. Tibial transverse transport (TTT), a mechanical intervention technique, has shown clinical efficacy in promoting DFU repair; however, its molecular mechanisms remain largely unclear. This study aimed to explore the role of microRNAs (miRNAs) in the TTT-mediated healing of DFUs and to elucidate their regulatory effects on fibroblast function under hyperglycemic conditions. A diabetic rabbit model with full-thickness foot ulcers was established and treated with TTT. Granulation tissue was harvested for transcriptome sequencing to identify differentially expressed miRNAs. Key candidates (miR-182-5p, miR-150-5p, miR-205-5p) were validated by RT-qPCR. In vitro experiments were conducted on fibroblasts cultured in high-glucose conditions, including gain-of-function assays to assess the impact of miR-182-5p on cell proliferation, migration, and expression of HIF-1α and VEGF. TTT significantly altered the miRNA expression profile in DFU granulation tissue, with miR-182-5p being the most upregulated. Functional studies revealed that miR-182-5p overexpression restored proliferation and migration of high-glucose-exposed fibroblasts, while enhancing HIF-1α/VEGF pathway activity. miR-150-5p and miR-205-5p were also elevated by TTT and may contribute to wound repair via PI3K/Akt activation and VEGFA modulation, respectively. These effects align with findings from recent high-impact studies. TTT promotes DFU healing not only through biomechanical stimulation but also via reprogramming of miRNA-mediated molecular pathways. miR-182-5p, in particular, plays a pivotal role in regulating fibroblast activity and angiogenic signaling, representing a promising target for adjunctive molecular therapies. This study provides novel mechanistic insight into TTT and supports its integration with miRNA-based strategies for enhanced DFU treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.